TIO Bioventures
  • About
  • Portfolio
  • News
  • Connect
Select Page

TIO Bio — Rachel Humphrey CMO PR 1.13.2020 SIR.docx

Jan 13, 2020

Recent Posts

  • Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia
  • Treadwell Announces Two Presentations at the 2020 ASH Annual Meeting Featuring Clinical Trial Updates on Lead Product Candidate, CFI-400945
  • Treadwell Announces Initiation New Clinical Trial CFI 400945
  • TIO-Bioventures-Launches-TCRyption-TCR-T-cell-based
  • Treadwell-Announces-Initiation-Patient-Dosing-TWT-101-Phase

Recent Comments

    ©2020 TIO Bioventures
    Terms of Use / Legal Disclaimer
    Design by D&CO
    New York Office
    41 Madison Avenue, 25th Floor
    New York, New York, USA, 10010

    Archives

    • April 2021
    • December 2020
    • October 2020
    • September 2020
    • August 2020
    • June 2020

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Whos theme My Theme | Powered by MyPress | Designed by Your Design Agency